Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643825 | 0.98 | HRH3 (0.42) | CYP1A2CYP3A4CYP2D6HRH3SIGMAR1 | |
| SCHEMBL2643623 | 0.88 | HRH3 (0.41) | HRH3SIGMAR1L3MBTL1HRH4 | |
| SCHEMBL2644874 | 0.84 | SIGMAR1 (0.41) | CYP3A4CYP2D6HRH3SIGMAR1L3MBTL1 | |
| SCHEMBL1906096 | 0.83 | SIGMAR1 (0.41) | CYP1A2HRH3SIGMAR1HTR2A | |
| SCHEMBL1968524 | 0.81 | HRH3 (0.42) | CYP2D6HRH3L3MBTL1HRH4 | |
| SCHEMBL935277 | 0.79 | HRH3 (0.39) | HRH3L3MBTL1HRH4 | |
| SCHEMBL4678193 | 0.75 | NOS3 (0.33) | SIGMAR1 | |
| SCHEMBL34468097 | 0.75 | NOS3 (0.48) | HRH3SIGMAR1HRH4 | |
| SCHEMBL2644533 | 0.75 | SIGMAR1 (0.49) | HRH3SIGMAR1L3MBTL1 | |
| SCHEMBL2644215 | 0.73 | SIGMAR1 (0.47) | CYP1A2HRH3SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238760-A1 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | RESEARCH TRIANGLE INSTITUTE (US) | 2009-09-24 | — | — | US | claimed |
| EP-2007374-A2 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | RESEARCH TRIANGLE INSTITUTE (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007124353-A2 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | RESEARCH TRIANGLE INSTITUTE (US) | 2007-11-01 | — | — | WO | claimed |
| US-20090238760-A1 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | RESEARCH TRIANGLE INSTITUTE (US) | 2009-09-24 | — | — | US | disclosed |
| EP-2007374-A2 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | RESEARCH TRIANGLE INSTITUTE (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007124353-A2 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | RESEARCH TRIANGLE INSTITUTE (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238760-A1 | ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME | NASP, CATSPER1, ACR | CYP1A2 327/4885CYP3A4 681/4885CYP2D6 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.